

17-B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (E), Mumbai - 400 093. INDIA.
Tel. : (91-22) 6645 5645
Fax : (91-22) 6645 5685

CIN No. L73100GJ2006PLC047837
Website : www.sunpharma.in

**SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.**



31st December 2015

To

The National Stock Exchange of India Ltd. BSE Limited
Exchange Plaza, 5th Floor, P J Towers,
Plot No. C/1, G Block, Dalal street,
Bandra Kurla Complex, Mumbai - 400001
Bandra (East),
Mumbai - 400 051.

Ref: *Scip Code: NSE: SPARC; BSE: 532872*

Sub: *Update on XELPROS™ (Latanoprost Ophthalmic Emulsion) and Elepsia XRTM (Levetiracetam extended-release tablets) NDAs"*

Dear Sir/ Madam,

We have received a communication from Sun Pharmaceutical Industries Ltd (SPIL), intimating us that it has received a Warning Letter from the US FDA for its facility located at Halol, Gujarat in India.

We had, in the past, informed that both XELPROS™ (Latanoprost Ophthalmic Emulsion) and Elepsia XR™ (Levetiracetam extended-release tablets 1000 mg and 1500 mg) are to be manufactured at (SPIL)'s Halol facility.

Further, we had informed through our press releases dated 1st Aug 2015 and dated 25th September 2015 about the receipt of Complete Response letter (CRL) by the Company for its New Drug Applications for XELPROS™ and Elepsia XR™ respectively from the U.S. Food and Drug Administration (USFDA).

Consequent to the above development, the management expects a possible further delay in the projected royalty income for the Company from the above mentioned products. The management is closely monitoring the development and has initiated steps to mitigate the possible adverse impact on the Company.

This is for your information and public dissemination.

Yours faithfully,

For Sun Pharma Advanced Research Company Limited


Debashis Dey

Company Secretary Regd. Office : SPARC, Akota Road, Akota, Baroda - 390 020.